Investigating receptor-mediated antibody transcytosis using Blood-Brain Barrier organoid arrays
Preprint
Abstract
Background: The pathways that control protein transport across the Blood-Brain Barrier (BBB) remain poorly characterized. Despite great advances in recapitulating the human BBB in vitro , current models are not suitable for systematic analysis of the molecular mechanisms of antibody transport. The gaps in our mechanistic understanding of antibody transcytosis hinder new therapeutic delivery strategy development. Methods: We applied a novel bioengineering approach to generate human BBB organoids by the self-assembly of astrocytes, pericytes and brain endothelial cells with unprecedented throughput and reproducibility using micro patterned hydrogels. We designed a semi-automated and scalable imaging assay to measure receptor-mediated transcytosis of antibodies. Finally, we developed a workflow to use CRISPR/Cas9 gene editing in BBB organoid arrays to knock out regulators of endocytosis specifically in brain endothelial cells in order to dissect the molecular mechanisms of receptor-mediated transcytosis. Results: BBB organoid arrays allowed the simultaneous growth of more than 5000 homogenous organoids per individual experiment in a highly reproducible manner. BBB organoid arrays showed low permeability to macromolecules and prevented transport of human non-targeting antibodies. In contrast, a monovalent antibody targeting the human transferrin receptor underwent dose- and time-dependent transcytosis in organoids. Using CRISPR/Cas9 gene editing in BBB organoid arrays, we showed that clathrin, but not caveolin, is required for transferrin receptor-dependent transcytosis. Conclusions: Human BBB organoid arrays are a robust high-throughput platform that can be used to discover new mechanisms of receptor-mediated antibody transcytosis. The implementation of this platform during early stages of drug discovery can accelerate the development of new brain delivery technologies.Keywords
All Related Versions
- Published version: Fluids and Barriers of the CNS, 18 (1), 1.
This publication has 39 references indexed in Scilit:
- Blood‐brain barrier transport using a high affinity, brain‐selective VNAR antibody targeting transferrin receptor 1The FASEB Journal, 2020
- Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeysScience Translational Medicine, 2020
- Enhanced Delivery of Galanin Conjugates to the Brain through Bioengineering of the Anti-Transferrin Receptor Antibody OX26Molecular Pharmaceutics, 2018
- Abstract 3631: Delivery of a CD20 transferrin receptor VNAR bispecific antibody to the brain for CNS lymphomaCancer Research, 2017
- Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primatesScience Translational Medicine, 2014
- A novel platform for engineering blood‐brain barrier‐crossing bispecific biologicsThe FASEB Journal, 2014
- Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular ShuttleNeuron, 2014
- Bispecific antibodies for delivery into the brainCurrent Opinion in Chemical Biology, 2013
- Glycemic Control and Chronic Dosing of Rhesus Monkeys with a Fusion Protein of Iduronidase and a Monoclonal Antibody Against the Human Insulin ReceptorDrug Metabolism and Disposition, 2012
- Science and the Fight Against BioterrorismThe FASEB Journal, 2002